Research and Development and License Agreements (Details) £ in Thousands						1 Months Ended				6 Months Ended	12 Months Ended
	Jul. 01, 2021 USD ($)	Oct. 11, 2020 USD ($)	May 12, 2019 USD ($)	Apr. 11, 2019 USD ($)	Jun. 06, 2017 GBP (£)	Sep. 17, 2021 USD ($)	Sep. 17, 2020	Aug. 25, 2020	Mar. 19, 2018	Jun. 30, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jan. 31, 2022 USD ($)	Sep. 30, 2021 USD ($)
Research and Development and License Agreements (Details) [Line Items]
Description of lipocure agreement									the LipoCure Agreement, the Company was required to pay an upfront fee upon signing of $150,000 and is required to make future milestone and royalty payments to LipoCure. The Company is obligated to make aggregate milestone payments of up to $19.8 million upon the achievement of specified development and commercial milestones. Royalty payments must be paid in an amount equal to a single digit to low double-digit percentage of annual net sales of royalty qualifying products, subject to certain adjustments. Royalties shall be payable during the period of time, on a country-by-country basis, commencing on the first commercial sale and ending upon the expiration of the last-to-expire patent claim on the licensed product, which is set to expire on July 24, 2030.
Nanomerics collaboration agreement, description				the Company entered into an exclusive collaboration and license agreement, as amended (the “Nanomerics Collaboration Agreement”), with Nanomerics Ltd., a company organized and existing under the laws of United Kingdom (“Nanomerics”), for the exclusive world-wide license to develop and commercialize products, including NES100, which contain hydrophilic neuropeptide Leucin5-Enkephalin and an amphiphile compound which is quaternary ammonium palmitoyl glycol chitosan, to engage in a collaborative program utilizing Nanomerics’ knowledge, skills and expertise in the clinical development of products and to attract external funding for such development.
Research service fees	$ 400,000
Description of cooperative research and development agreement								The term of the CRADA is for a period of four years from May 6, 2020 (the effective date of the agreement) and can be terminated by both parties at any time by mutual written consent.
Minimum [Member]
Research and Development and License Agreements (Details) [Line Items]
Royalty payments							5.00%
Maximum [Member]
Research and Development and License Agreements (Details) [Line Items]
Royalty payments							15.00%
MedPharm License Agreement [Member]
Research and Development and License Agreements (Details) [Line Items]
Milestone and royalty payments (in Pounds) | £					£ 1,150
Nanomerics Collaboration Agreement [Member]
Research and Development and License Agreements (Details) [Line Items]
Milestone payments				$ 103,000,000		$ 200,000
Royalty payments						$ 41,000,000
Yissum Research Agreement [Member]
Research and Development and License Agreements (Details) [Line Items]
Research service fees			$ 81,000
Description of yissum research agreement		the Company entered into an Agreement for Rendering of Research Services with Yissum (the “October 2020 Yissum Research Agreement”) on substantially similar terms and conditions as detailed above under the May 2019 Yissum Research Agreement. Under the October 2020 Yissum Research Agreement, the Company shall provide funding for research and development studies to be performed by researchers at Hebrew University related to the formulation of Liposomal Bupivacaine as well as efficacy and PK studies in animals. In consideration for the research services, the Company agreed to pay research service fees of $81,000 in six equal monthly installments. In connection with the completion of the Company’s IPO, the Company paid Yissum $40,500 towards the total consideration of $81,000. All services to be provided under the October 2020 Yissum Research Agreement were completed by June 30, 2021.
Research service fees paid in equal monthly installments		$ 81,000
Research and development expense		$ 81,000
Research and development in process										$ 337,500
Lipocure Research Agreement [Member]
Research and Development and License Agreements (Details) [Line Items]
Research service fees	$ 200,000
Research and development expense												$ 870,000
Research service fees paid in quarterly payments														$ 270,000
Lipocure payment												$ 250,000
Lipocure Research Agreement [Member] | Subsequent Event [Member]
Research and Development and License Agreements (Details) [Line Items]
Research service fees paid in quarterly payments													$ 270,000
Forecast [Member] | Lipocure Research Agreement [Member]
Research and Development and License Agreements (Details) [Line Items]
Additional payments											$ 270,000